Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation. 2024

Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
Regional Blood Transfusion Centre Swiss Red Cross Basel, Basel, Switzerland.

Elevated serum ferritin with/without HFE variants in asymptomatic persons leads frequently to referral for blood donation. Hemochromatosis (p.C282Y/p.C282Y) only requires treatment. We evaluated safety and feasibility of iron removal in healthy persons with elevated ferritin and HFE variants using blood donation procedures. Thirty subjects with ferritin >200 ng/mL (women) or >300 ng/mL (men) with p.C282Y/p.C282Y, p.C282Y/p.H63D or p.H63D/p.H63D were randomized to weekly phlebotomy (removal of 450 mL whole blood) or erythrapheresis (removal of 360 mL red blood cells) every 14 days. The ferritin target was <100 ng/mL. A full blood count and ferritin were measured at each visit. Hemoglobin (Hb) ≥140 g/L was required at inclusion. If Hb dropped to <120 g/L (women) or <130 g/L (men), procedures were postponed (7 or 14 days). Primary endpoint was the number of procedures needed to the ferritin target; secondary objectives were duration of treatment and compliance. The treatment effect was tested with Poisson regression; number of procedures and treatment duration were compared between study arms with the Kruskal-Wallis test. Twenty-five of 30 participants were men (83%); mean age was 47 years (SD 10.5), mean BMI 26.6 kg/m2 (SD 3.6); 17 had p.C282Y/p.C282Y, nine p.C282Y/p.H63D, four p.H63D/p.H63D. Median baseline Hb was 150 g/L (IQR 144, 1,559), median ferritin 504 ng/mL (IQR 406,620). Twenty-seven subjects completed the study. Treatment arm (p < 0.001) and HFE variant (p = 0.007) influenced the primary endpoint significantly. To ferritin levels <100 ng/mL, a median number of 7.5 (IQR 6.2, 9.8) phlebotomies and 4.0 (IQR 3.0, 5.8) erythraphereses (p = 0.001) was needed during a median of 66.5 days (IQR 49,103) and 78.5 days (IQR 46139), respectively (p = 0.448). Low Hb was the principal reason for protocol violation; anemia occurred in 13 participants (48%). Immediate complications were infrequent; fatigue was reported after 25% of phlebotomies and 45% of erythraphereses. Thirty-five procedures were postponed because of low Hb and 15 for non-medical reasons. The median interval was 7.0 (IQR 7.7) and 14.0 (IQR 14, 20) days between phlebotomies and erythraphereses, respectively. Blood donation procedures remove iron effectively in HC, but frequent treatments cause Hb decrease and fatigue that can impair feasibility.

UI MeSH Term Description Entries

Related Publications

Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
January 1999, Immunohematology,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
February 2012, British journal of haematology,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
January 2017, Parkinsonism & related disorders,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
December 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
June 2002, Mayo Clinic proceedings,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
January 2002, Scandinavian journal of clinical and laboratory investigation,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
January 2003, Blood cells, molecules & diseases,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
April 2000, Haematologica,
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
January 2009, Clinics (Sao Paulo, Brazil),
Laura Infanti, and Gerda Leitner, and Morten Moe, and Vildana Pehlic, and Marco Cattaneo, and Pascal Benkert, and Andreas Holbro, and Jakob Passweg, and Nina Worel, and Andreas Buser
November 2019, Saudi medical journal,
Copied contents to your clipboard!